Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hypertonic saline · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days |
| Hypertonic Saline | EXPERIMENTAL | Hypertonic saline (3%), 3mL every 6hrs for up to 7 days |
| Name | Type | Description |
|---|---|---|
| Hypertonic saline (3%) | DRUG | 3mL of HTS given via nebulizer every 6hrs |
| Placebo (0.9% saline) | DRUG | 3mL of normal saline given via nebulizer every 6hrs |
Inclusion Criteria: * invasive mechanical ventilation of \< 12 hrs duration prior to enrollment * expected duration of mechanical ventilation of \> 48hrs from enrollment * age \< 18yo Exclusion Criteria: * inclusion in another clinical study * cystic fibrosis * status asthmaticus * pulmonary hemo...
Hypertonic saline is being studied for use in respiratory failure. It is administered as a nebulized solution for mechanically ventilated children. The investigational treatment is currently in Phase 1 clinical development.
Hypertonic saline is being developed by Community Health Systems, Inc., a company traded on the New York Stock Exchange under the ticker symbol CYH.
Hypertonic saline is in Phase 1 clinical development. It is an investigational small molecule being studied for respiratory failure and has not been approved by the FDA.
Hypertonic saline has one completed clinical trial, NCT01945944, titled "Nebulized Hypertonic Saline for Mechanically Ventilated Children." The trial enrolled 18 participants in the United States and was a randomized, double-blind, placebo-controlled study.
Yes, Hypertonic saline is classified as a small molecule therapeutic. It is being investigated as a nebulized treatment for respiratory failure in pediatric patients on mechanical ventilation.